12
Views
0
CrossRef citations to date
0
Altmetric
LETTER

Critique on “Real-World Effectiveness of First-Line Lenvatinib Therapy in Advanced Hepatocellular Carcinoma: Current Insights” [Letter]

ORCID Icon, &
Pages 89-90 | Received 20 Jun 2024, Accepted 21 Jun 2024, Published online: 01 Jul 2024

References

  • Biachi de Castria T, Kim RD. Real-world effectiveness of first line lenvatinib therapy in advanced hepatocellular carcinoma: current insights. Pragm Observ Res. 2024;15:79–87. doi:10.2147/POR.S395974
  • Hatanaka T, Naganuma A, Kakizaki S. Lenvatinib for hepatocellular carcinoma: a literature review. Pharmaceuticals. 2021;14(1):36. doi:10.3390/ph14010036
  • Goyal MK, Singh A, Kumar Gupta Y, Kaur Dhaliwal K, Sood A. Lenvatinib-induced tumor lysis syndrome in advanced hepatocellular carcinoma. ACG Case Rep J. 2023;10(9):e01139. doi:10.14309/crj.0000000000001139
  • Dipasquale A, Marinello A, Santoro A. A comparison of lenvatinib versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma: selection criteria to guide physician’s choice in a new therapeutic scenario. J Hepatocell Carcinoma. 2021;8:241–251. doi:10.2147/JHC.S270532